FDA Brief

Warning letters Drugs

FDA warning letter to

Shenzhen Hengkaifeng Commerce and Trade Co., Ltd

LowIssued May 6, 2025Posted May 27, 2025Center for Drug Evaluation and Research (CDER)

Shenzhen Hengkaifeng's Sensitivity Toothpastes listing was inaccurate, making the drug misbranded, FDA says.

What happened

FDA reviewed the firm’s electronic drug listing for Sensitivity Toothpastes (NDC 84117-013) and found the listed active ingredient was hydrated silica, while the label lists potassium nitrate 5% and sodium fluoride 0.1%. FDA also found the listing said liquid and oral, while the label says foam for dental administration. FDA had sent listing deficiency and data removal notices before this letter.

What FDA found

  1. The listing did not give the correct active ingredient names and quantities, because it listed hydrated silica while the label lists potassium nitrate 5% and sodium fluoride 0.1%.

    21 CFR 207.49(a)(4)
  2. The listing did not give the correct dosage form and route of administration, because it listed liquid and oral while the label says foam for dental administration.

    21 CFR 207.49(a)(6) & (11)
  3. FDA says the firm did not meet its drug listing obligations.

    section 510(j) of the FD&C Act, 21 U.S.C. 360(j); section 301(p), 21 U.S.C. 331(p)
  4. FDA says the product is misbranded because it is not properly listed with FDA.

    section 502(o) of the FD&C Act, 21 U.S.C. 352(o)
  5. FDA says introducing or delivering the misbranded drug into interstate commerce is prohibited.

    section 301(a) of the FD&C Act, 21 U.S.C. 331(a)

What FDA wants

FDA asks the firm to notify it in writing within 15 working days of receipt of the specific steps taken to correct the violations, including explanations and supporting documents; if corrective actions cannot be completed, the firm must state why and give a timeframe.

Who should pay attention

  • companies responsible for NDC drug listings
  • distributors or sellers of foreign-made drug products
  • regulatory staff handling eDRLS listing data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk